RT Journal Article
SR Electronic
T1 FRET-based screening in HEK293T identifies p38 MAPK and PKC inhibition as therapeutic targets for α-synuclein aggregation
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.02.16.431382
DO 10.1101/2021.02.16.431382
A1 Alexander Svanbergsson
A1 Fredrik Ek
A1 Isak Martinsson
A1 Jordi Rodo
A1 Di Liu
A1 Edoardo Brandi
A1 Caroline Haikal
A1 Laura Torres-Garcia
A1 Wen Li
A1 Gunnar Gouras
A1 Roger Olsson
A1 Tomas Björklund
A1 Jia-Yi Li
YR 2021
UL http://biorxiv.org/content/early/2021/02/16/2021.02.16.431382.abstract
AB Aggregation of α-synuclein is associated with neurodegeneration and a hallmark pathology in synucleinopathies. These aggregates are thought to function as prion-like particles where the conformation of misfolded α-synuclein determines the induced pathology’s traits similar to prion diseases. Still, little is known about the molecular targets facilitating the conformation-specific biological effects, but their identification could form the basis for new therapeutic intervention. High-throughput screening (HTS) of annotated compound libraries could facilitate mechanistic investigation by identifying targets with impact on α-synuclein aggregation. To this end, we developed a FRET-based cellular reporter in HEK293T cells, with sensitivity down to 6.5 nM α-synuclein seeds. Using this model system, we identified GF109203X, SB202190, and SB203580 as inhibitors capable of preventing induction of α- synuclein aggregation via inhibition of p38 MAPK and PKC, respectively. Our findings highlight the value HTS brings to the mechanistic investigation of α-synuclein aggregation while simultaneously identifying novel therapeutic compounds.Competing Interest StatementThe authors have declared no competing interest.